VVOS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -7.97%, SMA50 -21.71%, SMA200 -51.89%). The stock’s 14-day RSI is 34.7 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.76% below its high and over 1.86% above its low. Average 10-day trading volume of 163.31 thousand shares is below the 3-month average of 221.11 thousand, indicating normal recent market interest.

Vivos Therapeutics, Inc. has 7.50 million shares outstanding. The public float is 5.43 million shares, elevated short interest at 2.81% of float. This equals 194.29 thousand shares. The short ratio is 1.11 days. Institutional investors hold 10.85% of the float. Insiders own 26.47%. Skaff Michael C holds 429.96 thousand shares, Huntsman Ronald Kirk has 86.52 thousand shares and Amman Bradford K. has 2.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) closed at $0.61 USD, gaining $0.03 (4.65%) from the previous close of $0.58. The stock is currently mid-range between its 52-week high and low $0.55 and $7.95. With a market capitalization of about $3.60 million, Vivos Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~6.21). Key stats such as the average daily volume over the past year has been around 222.88 thousand shares, volume is running light vs its 52-week average. Headquartered in Highlands Ranch, CO, Vivos Therapeutics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO R. Kirk Huntsman, the company employs approximately 109 people and listed since December 11, 2020. Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

Vivos Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 32.77%. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at -$0.48. Next year's EPS is expected at $59.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.50. The high target offers 1106.9% upside. The low target suggests 331.03% downside. The mean target is $5.10. This offers 779.31% upside. Vivos Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 20, 2026, missed forecasts by 44.44%. The prior quarter beat by 17.17%. Over the last six quarters, Apple has recorded several small beats. These include -34.88% in March 31, 2025.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares are flat -2.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vivos Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.24, suggesting 796.03% upside. Our AI forecast model points to short-term weakness (-36.73% over two weeks), a medium-term rise (151.37% over three months), and a longer-term loss (-98.29% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vivos Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -36.73%, with price expected at $0.37 by June 03, 2026, within a range of $0.26 to $0.48 3-Month Outlook: Projected rise of 151.37%, reaching $1.47 by August 19, 2026, with a range of $1.27 to $1.60. 1-Year Outlook: Projected loss of -98.29%, with price at $0.01 by May 21, 2027, within a range of $0.00 to $0.59.

Vivos Therapeutics, Inc. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 0.17 and a price-to-book ratio of -7.07 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.18, also below market averages.